UK healthcare cost agency rejects J & J's nasal spray for depression

Britain's healthcare cost agency on Tuesday recommended against including Johnson& Johnson's nasal spray for depression, Spravato, in the country's healthcare network, citing uncertainties over its clinical and cost effectiveness.

Source: Reuters: Health - January 28, 2020 Category: Consumer Health News Tags: healthNews Source Type: news